Work

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

Year: 2021
Type: article
Abstract: B-cell maturation antigen (BCMA) is an attractive therapeutic target highly expressed on differentiated plasma cells in multiple myeloma and other B-cell malignancies. GSK2857916 (belantamab mafodotin, BLENREP) is a BCMA-targeting antibody–drug conjugate approved for the treatment of relapsed/refractory multiple myeloma. We report that GSK2857916 induces immunogenic cell death in BCMA-expressing cancer cells and promotes dendritic cell activation in vitro and in vivo. GSK2857916 treatment enhances intratumor immune cell infiltration and activation, delays tumor growth, and promotes durable complete regressions in immune-competent mice bearing EL4 lymphoma tumors expressing human BCMA (EL4-hBCMA). Responding mice are immune to rechallenge with EL4 parental and EL4-hBCMA cells, suggesting engagement of an adaptive immune response, immunologic memory, and tumor antigen spreading, which are abrogated upon depletion of endogenous CD8+ T cells. Combinations with OX40/OX86, an immune agonist antibody, significantly enhance antitumor activity and increase durable complete responses, providing a strong rationale for clinical evaluation of GSK2857916 combinations with immunotherapies targeting adaptive immune responses, including T-cell–directed checkpoint modulators.
Authors: Rocio Montes de Oca(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing), Alireza S. Alavi(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Visualization, Writing – original draft, Writing – review & editing), Nick Vitali(Formal analysis, Investigation, Methodology), Sabyasachi Bhattacharya(Conceptualization, Formal analysis, Investigation, Methodology, Writing – review & editing), Christina Blackwell(Conceptualization, Formal analysis, Investigation, Methodology, Writing – review & editing), Krupa Patel(Conceptualization, Formal analysis, Investigation, Methodology, Writing – review & editing), Laura Seestaller-Wehr(Conceptualization, Formal analysis, Investigation, Methodology, Writing – review & editing), Heather Kaczynski(Formal analysis, Investigation, Methodology), Hong Shi(Formal analysis, Investigation, Methodology, Writing – review & editing), Eric Dobrzynski(Investigation, Methodology, Writing – review & editing), Leslie Obert(Formal analysis, Investigation), Lyuben Tsvetkov(Conceptualization, Formal analysis, Investigation), David C. Cooper(Formal analysis, Writing – review & editing), Heather Jackson(Formal analysis, Writing – review & editing), Paul Bojczuk(Investigation, Methodology), Sabrina Forveille(Investigation, Methodology), Oliver Kepp(Conceptualization, Formal analysis, Methodology, Supervision, Writing – review & editing), Allan Sauvat(Investigation, Methodology), Guido Kroemer(Conceptualization, Funding acquisition, Resources, Writing – review & editing), Mark Creighton-Gutteridge(Methodology), Jingsong Yang(Conceptualization, Supervision), Chris Hopson(Resources, Supervision), Niranjan Yanamandra(Resources, Supervision), Christopher Shelton(Formal analysis, Resources, Writing – review & editing), Patrick Mayes(Conceptualization, Supervision), Joanna Opalinska(Funding acquisition, Writing – review & editing), Mary Barnette(Funding acquisition, Resources), Roopa Srinivasan(Funding acquisition, Resources), James Smothers(Funding acquisition, Resources), Axel Hoos(Funding acquisition, Resources)
Language: English
Subfield: Immunology
Open Access status: hybrid
OpenAlex ID: W3177941998
FWCI: 6.287
Cites: 50
Cited by: 133
Related to: 10